Scientific article

Maladies cardiovasculaires, antiagrégants, anticoagulants et risque hémorragique

Other titleCardiovascular diseases, antiplatelet agents, anticoagulants and hemorrhagic risk
Published inRevue médicale suisse, vol. 6, no. 267, p. 1942,1944-1946,1948-1950
Publication date2010

If the benefits of antiplatelet and anticoagulant therapies are well established, bleeding complications appear underestimated in trials in comparison to their real-life incidence. Also, a large number of patients receive various associations of antiplatelet or anticoagulant treatments, while the benefit of some associations is not firmly established and data about their safety are missing. Identifying patients at high risk of bleeding is essential to define appropriate strategies. In this article we discuss the risk-benefit of various antiplatelet and anticoagulant molecules taken individually or in combination. An overview of the main clinical scores available to stratify the risk of bleeding is presented.

  • Anticoagulants/administration & dosage/*adverse effects
  • Hemorrhage/*chemically induced
  • Humans
  • Myocardial Infarction/*prevention & control
  • Platelet Aggregation Inhibitors/administration & dosage/*adverse effects
  • Risk Assessment
  • Stroke/*prevention & control
Citation (ISO format)
EUSEBIO, Jorge et al. Maladies cardiovasculaires, antiagrégants, anticoagulants et risque hémorragique. In: Revue médicale suisse, 2010, vol. 6, n° 267, p. 1942,1944–1946,1948–1950.
ISSN of the journal1660-9379

Technical informations

Creation05/22/2012 3:15:07 PM
First validation05/22/2012 3:15:07 PM
Update time03/14/2023 5:29:42 PM
Status update03/14/2023 5:29:42 PM
Last indexation01/15/2024 11:37:14 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack